Form 4: Acrivon Therapeutics Executive Reports Tax Withholding Transaction
SEC Form 4 Filing
Kristina Masson, EVP of Business Operations at Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On August 14, 2024, Kristina Masson, EVP of Business Operations at Acrivon Therapeutics, had 490 shares of common stock withheld by the issuer to satisfy tax obligations.
- The shares were withheld at a price of $7.02 per share.
- Following the transaction, Masson directly owns 317,246 shares of Acrivon Therapeutics common stock.
- Masson also has indirect beneficial ownership of 2,502,129 shares held by her spouse, Peter Blume-Jensen, the President and CEO of Acrivon Therapeutics, but disclaims beneficial ownership except to the extent of her pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a tax withholding transaction, which has a neutral sentiment.
Management Comments
- Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors regarding ownership changes.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of the transaction where shares were withheld for tax obligations. |
| 08/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.